ONCOLYTICS BIOTECH INC. Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
ONCOLYTICS BIOTECH INC. (ONCY) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of CAD 0 for the 12-month period ending 2024-12-31, per its 20-F filed 2025-03-07.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2025-03-07
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2024-12-31 | 0.00 CAD 20-F · filed 2025-03-07 |
| 2023-12-31 | 151.00K CAD 20-F · filed 2025-03-07 |
| 2022-12-31 | 0.00 CAD 20-F · filed 2025-03-07 |
| 2021-12-31 | 0.00 CAD 20-F · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |